PhRMA Statement on President Trump’s Signing of PDUFA VI Reauthorization

Washington, D.C. (August 18, 2017) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:

“PhRMA commends President Trump for signing into law the FDA Reauthorization Act of 2017 (FDARA), which includes the Prescription Drug User Fee Amendments of 2017 (PDUFA VI), as well as the biosimilar and generic drug user fee amendments. In today’s new era of medicine, where breakthrough science is transforming patient care, today’s signing of FDARA is a major victory for the patients in need of innovative, lifesaving treatments.

"By reauthorizing PDUFA and the other user fees, the administration is leading the way toward greater efficiency at the U.S. Food and Drug Administration (FDA) and increasing competition in the biopharmaceutical market.

“We further appreciate the leadership that Health and Human Services Secretary Tom Price and FDA Commissioner Scott Gottlieb demonstrated throughout this reauthorization process.”

To learn more about PDUFA, please visit

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $900 billion in the search for new treatments and cures, including an estimated $79.6 billion in 2018 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit: